Humana Inc.

Humana Inc. (NYSE: HUM), commonly "Humana," is a publicly traded managed-care and health-services company headquartered at 500 W. Main St., Louisville, Kentucky. It was founded in 1961 (incorporated in 1964) and is not a subsidiary. Fortune's 2026 listing reports roughly 67,000 employees, revenue of about $129.7 billion, and market value of roughly $20.8 billion; James A. Rechtin is listed as CEO. Humana is one of the largest administrators of Medicare Advantage plans and operates in all 50 states.

The company reports two segments. Its Insurance segment covers Medicare Advantage (individual and group), stand-alone Medicare Part D prescription drug plans, Medicare Supplement, state-based Medicaid and dual-eligible contracts, employer-group commercial fully-insured and specialty benefits (dental, vision, life), administrative-services-only (ASO) arrangements, and military services. Its CenterWell segment covers pharmacy solutions (PBM), senior-focused primary care centers, and home health and hospice operations.

Humana is an operating company, not a non-practicing entity. In the tracked data it appears once, solely as plaintiff in Humana Inc. v. Celgene Corp., D.N.J., and never as a defendant — the opposite pattern from a PAE. Notably, that case is scored as a patent-related matter but is pleaded as an antitrust action (pay-for-delay / sham litigation), not a patent-infringement suit, and it was filed in the District of New Jersey rather than a plaintiff-friendly patent venue such as the Eastern District of Texas.

That case, filed February 28, 2019, was consolidated into In re Revlimid & Thalomid Purchaser Antitrust Litigation, No. 2:19-cv-07532 (D.N.J.), alongside suits by Blue Cross Blue Shield Association, Health Care Service Corporation, Cigna, and Molina Healthcare. Humana alleged Celgene suppressed generic competition for Revlimid (lenalidomide) and Thalomid (thalidomide) via sample denials, patent prosecutions, sham litigation, a citizen petition, and a settlement with Natco Pharma. On September 29, 2026, the court denied in relevant part the defendants' motion to dismiss the pay-for-delay claims. Celgene is now part of Bristol-Myers Squibb.